Dr. Hyi-Man Park oversees the research and development initiatives for PRISM BioLab as Head of the Research and Development Department. Prior to joining PRISM BioLab, he was the Head of Biology at RaQualia Pharma Inc., which is a spin-off from the Pfizer Research Center Japan. Before RaQualia, he was at the Novartis Institute for BioMedical Research (NIBR), located in Cambridge, where he worked on initiating/leading novel drug projects in the cardiovascular and oncology area. He led projects from the target identification to preclinical stage. He serves as an Industry Advisor of the SPARK Translational Medicine program of Stanford University, and was a Designated Professor of Nagoya University. He received his undergraduate and PhD degrees from Naogya University and completed his Post-doc at University of Minnesota. His Ph.D. research elucidated transcriptional regulation by steroid hormones.